Cancer Medicine · global
Phase 3 trial of personalized mRNA cancer vaccine: 42% lower risk of recurrence or death after melanoma surgery
By turning a tumor’s unique features into recognition cues for the immune system, a personalized cancer vaccine improved recurrence-free survival after surgery in a trial of 1,137 people. However, whether it can extend overall survival requires further follow-up, and the treatment is not yet available for routine use.
After surgery to remove melanoma, patients may still face the risk of their cancer returning. A large phase 3 clinical trial shows that adding an mRNA vaccine tailored to each patient’s tumor to postoperative immunotherapy can further reduce the risk of recurrence or death, moving personalized cancer vaccines from the promise of early research toward more robust evidence in humans.
Merck and Moderna announced detailed results from the INTerpath-001 trial on October 22. The randomized, double-blind study enrolled 1,137 patients with stage IIB to IV melanoma whose tumors had been completely removed, comparing intismeran autogene plus the immunotherapy drug pembrolizumab with placebo plus pembrolizumab. Melanoma Institute Australia said the trial spanned 157 study centers worldwide and that participants had not previously received cancer drug treatment.
After a median follow-up of 24.6 months, the risk of recurrence or death was 42% lower in the vaccine combination group than in the control group, with a hazard ratio of 0.58 and a 95% confidence interval of 0.45 to 0.75, reaching statistical significance. Two-year recurrence-free survival rates were 82.2% and 70.0%, respectively, a difference of 12.2 percentage points. This also makes clear that 42% refers to the relative reduction in risk during follow-up; it cannot be interpreted as an additional 42 out of every 100 patients remaining free of recurrence. The relative risk of distant metastasis or death was reduced by 38%.
The vaccine’s design starts with the “neoantigens” unique to each patient’s tumor—abnormal protein features produced by mutations in cancer cells that the immune system can recognize. The research team uses DNA information from tumor and normal tissue to select recognition targets, then makes mRNA carrying the corresponding instructions, prompting the body to display these features and trigger a T-cell response. Pembrolizumab, given alongside the vaccine, blocks the PD-1 immune suppression signal. By addressing target recognition and relieving immune suppression, respectively, the two treatments aim to eliminate cancer cells that may remain after surgery.
Alongside efficacy, the burden of additional treatment must also be weighed. The companies reported grade 3 to 5 treatment-related adverse event rates of 14.2% in the vaccine combination group and 13.4% in the control group; common adverse events in the combination group included fever, injection-site pain, and fatigue. BioPharma Dive separately reported that approximately 7% and 5% of patients in the two groups discontinued treatment because of adverse events. These data show that the rates of higher-grade adverse events were similar between the groups, but adding the vaccine still brings additional discomfort and a risk of treatment discontinuation.
These results come from a phase 3 study, distinct from the smaller phase 2 trial conducted previously. According to BioPharma Dive, the European Society for Medical Oncology released the results ahead of the scheduled conference presentation after screenshots of the study data leaked early. The clearest evidence at present is that this combination can improve recurrence-free survival after surgery in certain patients with melanoma. Overall survival data are not yet mature, so these results cannot yet support claims that the treatment extends life or improves cure rates.
Intismeran is a therapeutic vaccine used after diagnosis, intended to reduce recurrence after surgery; it is not a vaccine for healthy people to prevent cancer. Melanoma Institute Australia said the treatment remains investigational and is not yet available outside trials. For patients, beyond awaiting regulatory review, long-term follow-up is needed to answer how long this lower risk of recurrence can last and whether it can ultimately translate into longer lives.